Glenzocimab
Sponsors
Hopital Fondation Adolphe De Rothschild, Assistance Publique Hopitaux De Paris, Acticor Biotech, Assistance Publique - Hôpitaux de Paris, Fondation Ophtalmologique Adolphe de Rothschild
Conditions
ARDSAcute Ischemic StrokeAcute Respiratory Distress SyndromeAcute ischemic strokeCOVID-19Ischemic stroke with Large CoreSARS-CoV InfectionStroke, Acute
Phase 2
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
CompletedNCT04659109
Start: 2020-12-16End: 2021-08-06Updated: 2021-09-13
Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study
Not yet recruitingNCT05559398
Start: 2022-10-10End: 2026-10-10Target: 260Updated: 2022-09-29
Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy
Not yet recruitingCTIS2023-509615-92-00
Target: 304Updated: 2024-05-22
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
Not yet recruitingNCT06437431
Start: 2026-09-30End: 2030-10-31Target: 304Updated: 2025-06-25
GREEN A randomized, double-blind, multi-center, placebo-controlled, efficacity and safety study of glenzocimab used as an add-on therapy on top of mechanical thrombectomy for acute ischemic stroke
CompletedCTIS2024-514352-32-00
Start: 2023-01-03End: 2025-07-30Target: 260Updated: 2024-10-07